 
    Gensciences develops drugs that focus on underserved illnesses like hemophilia, metabolic diseases, and anti-tumor fields.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 4, 2021 | Series A | — | 1 | — | — | Detail | 
| Mar 4, 2021 | Series B | — | 1 |  | — | Detail | 
| Investor Name | Lead Investor | Funding Round | 
|---|---|---|
|  | Yes | Series B | 
|  Hygeia Capital LLC | — | Series A |